France is experiencing supply tensions affecting the antidepressant Prozac and its generic versions, according to reports from 20 Minutes, BFM, TF1 Info and lanouvellerepublique.fr. The strain concerns fluoxetine 20 mg, the active ingredient sold under the brand name Prozac. France's medicines regulator, the ANSM, has published a situation update on the tensions.
According to TF1 Info and lanouvellerepublique.fr, safety stock has been made available to help cover demand. BFM reported that production is under such pressure that exporting the drug has been prohibited.
The reports, published on Friday, describe the situation as a supply tension rather than a confirmed nationwide shortage, though the exact scope and duration are not detailed in the available material. The ANSM's update specifically addresses the 20 mg dose of fluoxetine, the formulation at the centre of the reports.
Fluoxetine is widely prescribed for depression and related conditions, which means any disruption to its availability can affect a large number of patients in France. The decision to release safety stock and to restrict exports indicates that authorities are treating the situation as serious enough to warrant active measures.
It is not clear from the reporting how long the tensions are expected to last or which manufacturers are most affected. Patients and pharmacists will be watching for further guidance from the ANSM on availability and any recommendations on alternatives.
